Hospira Vinorelbine Tartrate for Injection 50 mg/5 mL vial

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

vinorelbine tartrate, Quantity: 13.85 mg/mL

Verfügbar ab:

Hospira Australia Pty Ltd

INN (Internationale Bezeichnung):

Vinorelbine tartrate

Darreichungsform:

Injection

Zusammensetzung:

Excipient Ingredients: water for injections

Verabreichungsweg:

Intravenous

Einheiten im Paket:

1 x 5 mL vial

Klasse:

Medicine Listed (Export Only)

Verschreibungstyp:

Not scheduled. Not considered by committee

Anwendungsgebiete:

Vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (NSCLC), as a single agent or in combination. Vinorelbine tartrate is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. In addition, vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

Produktbesonderheiten:

Visual Identification: A clear, colourless to pale yellow solution & free from visible particulates; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Berechtigungsstatus:

Licence status A

Berechtigungsdatum:

2008-05-05